Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 9/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10563682 | 0.98 | EPHX1 (0.50) | EPHX1ACHENAAACA12CA1 | |
| SCHEMBL10564570 | 0.93 | ALDH1A1 (0.45) | EPHX1ACHECA12CA1CA2 | |
| SCHEMBL2942928 | 0.93 | EPHX1 (0.61) | EPHX1ACHENAAACA12CA1 | |
| SCHEMBL4882104 | 0.93 | EPHX1 (0.61) | EPHX1ACHENAAACA12CA1 | |
| SCHEMBL5162543 | 0.91 | EPHX1 (0.59) | EPHX1ACHENAAACA12CA1 | |
| SCHEMBL5164102 | 0.89 | EPHX1 (0.56) | EPHX1ACHENAAACA12CA1 | |
| SCHEMBL5163094 | 0.86 | EPHX1 (0.47) | EPHX1ACHETSHR | |
| SCHEMBL10563632 | 0.85 | HPGD (0.41) | ACHE | |
| SCHEMBL4430601 | 0.85 | EPHX1 (0.50) | EPHX1ACHETSHR | |
| SCHEMBL5161708 | 0.84 | EPHX1 (0.47) | EPHX1ACHENAAACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2117718-B1 | NOVEL DITHIOCARBAMATE COLLECTORS AND THEIR USE IN THE BENEFICATION OF MINERAL ORE BODIES | CYTEC TECH CORP (US) | 2017-05-10 | — | — | EP | disclosed |
| US-8376142-B2 | Dithiocarbamate collectors and their use in the beneficiation of mineral ore bodies | CYTEC TECHNOLOGY CORP. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20080185317-A1 | NOVEL DITHIOCARBAMATE COLLECTORS AND THEIR USE IN THE BENEFICIATION OF MINERAL ORE BODIES | CYTEC TECHNOLOGY CORP. | 2008-08-07 | — | — | US | disclosed |
| US-4659853-A | Process for the production of isothiocyanate derivatives | AMERICAN CYANAMID COMPANY (US) | 1987-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080185317-A1 | NOVEL DITHIOCARBAMATE COLLECTORS AND THEIR USE IN THE BENEFICIATION OF MINERAL ORE BODIES | FTH1, FECH, SLC40A1 | EPHX1 4250/4885ACHE 2006/4885NAAA 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.